Haleon Pakistan Limited (PSX: HALEON) has recently revealed its plans to inject $10 million into its manufacturing facility located in Jamshoro. The investment is geared towards scaling up the production of the Panadol base portfolio, encompassing Panadol 500mg and Panadol Extra tablets. The company, in its disclosure to the local stock exchange, emphasized its commitment to incorporating the latest manufacturing technology within Pakistan, with the goal of boosting the manufacturing capacity to an impressive 8 billion tablets.
The strategic move is intended to ensure seamless and consistent supplies of Pakistan’s leading pharmaceutical and over-the-counter medicines, vital for meeting the healthcare needs of consumers and patients across the country.
Notably, this substantial investment complements the ongoing efforts of Haleon Pakistan Limited to further enhance its manufacturing capabilities. An additional $2 million is being allocated towards the expansion of the manufacturing facility for the company’s flagship brand, CaC 1000 Plus. This initiative aims to cater to both local demands and the emerging export opportunities that the company is actively pursuing.
The announcement highlighted the approval of the investment and associated financing by the company’s Board of Directors (BoD), underscoring their strategic commitment to strengthening the local manufacturing sector and contributing to the growth of the pharmaceutical industry in Pakistan.
At the time of reporting, Haleon Pakistan Limited’s shares were observed to be trading at Rs164.07, indicating an increase of 11.45 rupees or 7.50% in comparison to the previous day’s closing rate.
HALEON is primarily focused on the manufacturing, marketing, and distribution of consumer healthcare and over-the-counter health products, reflecting the company’s steadfast dedication to promoting accessible and high-quality healthcare solutions for the Pakistani market.
